In April 2020, ZS surveyed 388 physicians, nearly 500 patients and ~ 30 hospital administrators for a pulse of COVID-19 implications. The results highlight what pharma companies should do next, including:

  • Managing disruption to care
  • Perspectives on the new normal
  • The evolving role of pharma